NCT04460066 - A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2020

Primary Completion Date

December 6, 2021

Study Completion Date

July 15, 2023

Conditions

Esophageal Cancer

Interventions

DRUG

anti-PD-L1 antibody

Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.

DRUG

albumin bound paclitaxel

Patients will receive 4 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .

DRUG

cisplatin

Patients will receive 4 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.

DRUG

placebo

Patients will receive 4 cycles of placebo IV on day 1 every 3 weeks.

PROCEDURE

radical resection of esophageal carcinoma

Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.

Trial Locations (1)

Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing